Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X:
“՛CRISPR-Cas9 Clinical Safety: Off-Target Assessment Framework — A recently published review highlights the need for advanced strategies to address off-target effects, the most significant challenge in therapeutic genome editing.
CRISPR-Cas9 Overview
CRISPR-Cas9 uses programmable nucleases comprising Cas9 endonuclease and guide RNA (gRNA) to create targeted double-strand breaks with base-pair precision. Current therapeutic applications include treating β-hemoglobinopathies via BCL11A enhancer targeting, demonstrated by Casgevy—the first FDA-approved CRISPR therapy.
Off-Target Effects -Critical Safety Challenge
Off-target activity occurs when CRISPR-Cas9 cleaves unintended genomic loci, potentially:
- Disrupting tumor suppressor genes or proto-oncogenes
- Generating large structural variants (deletions, inversions, translocations)
- Causing chromosomal instability and potential malignant transformation
Clinical reality: Over 100 active CRISPR clinical trials are underway, yet safety assessment protocols remain inconsistent.
Five-Tier Safety Assessment Framework
The authors propose a clear five-step safety evaluation:
1. Computational gRNA Design
In silico prediction tools identify potential off-target sites
High-fidelity Cas variants reduce off-target binding
2. Experimental Off-Target Nomination
Cell-free and cell-based assays provide genome-wide detection
Orthogonal validation using multiple methodologies
3. Structural Variant Detection
Long-read sequencing identifies large deletions and rearrangements
Digital PCR quantifies specific variants with high sensitivity
4. Functional Safety Assessment
In vitro transformation assays evaluate oncogenic potential
Single-cell sequencing links genotype to phenotype
5. Regulatory Compliance
GMP-grade manufacturing ensures consistent quality
FDA/EMA guidelines mandate comprehensive characterization
Personalized Safety Considerations
Population-specific variants can create or eliminate off-target sites. Solution: Variant-aware prediction tools incorporate individual genetic profiles to identify population-specific or patient-specific risks.
The Path Forward
Standardizing rigorous safety frameworks while maintaining innovation pace remains the key challenge. As CRISPR transitions from experimental tool to clinical standard, comprehensive off-target assessment becomes scientifically essential and ethically imperative for patient safety.
Congratulations to Nechama Kalter and co-authors.”
Read the full article here.
Title: Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
Authors: Nechama Kalter, Carla Fuster-García, Alfredo Silva, Víctor Ronco-Díaz, Stefano Roncelli, Giandomenico Turchiano, Jan Gorodkin, Toni Cathomen, Karim Benabdellah, Ciaran Lee, Ayal Hendel
Stay updated on the latest scientific advances with Hemostasis Today.
-
Aug 16, 2025, 14:00Iron Deficiency in Polycythemia Vera: William Aird Reveals JAK2-Driven Erythropoiesis as The Key Cause
-
Aug 15, 2025, 23:36Irene M Lang's Editorial on Getting Risk Assessment Right in Acute Pulmonary Embolism
-
Aug 15, 2025, 23:31Richard Buka: Many Improvements Needed in HIT Management
-
Aug 15, 2025, 23:29Cathy Harrison: Launching A Journal Club from EAHAD and WFH
-
Aug 15, 2025, 23:24PERT 2025 Symposium Session XIII: Expert Insights on CTEPH Diagnosis, Surgery and BPA Innovations - Join the Conversation
-
Aug 16, 2025, 16:33RPTH Journal: Dietmar Fries and Colleagues Explore Impact of Long-Distance Trail Running on Blood Markers
-
Aug 16, 2025, 16:15Josepha Clara Sedzro: First Cryo-EM Structure of the Coagulation Initiation Complex
-
Aug 16, 2025, 15:03Abdulla Damluji Highlights ASPREE Trial Update
-
Aug 16, 2025, 14:54Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing
-
Aug 16, 2025, 13:42LMWH Use for VTE Prophylaxis in COVID-19 Hospitalized Patients - Multicenter Data from China
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman